Top Markets
#1 Pleasing Gold Pleasing Gold +1,501.26%
#2 Ontology Gas Ontology Gas +68.00%
#3 PulseChain PulseChain +58.48%
#4 BOOK OF MEME BOOK OF MEME +33.91%
#5 Merlin's Seal BTC Merlin's Seal BTC +33.60%
#6 ConstitutionDAO ConstitutionDAO +33.54%
#7 Neiro Neiro +28.42%
#8 Collect on Fanable Collect on Fanable +27.59%
#9 Pump.fun Pump.fun +23.48%
#10 Unit Pump Unit Pump +23.48%
Coin of the day
Pleasing Gold Pleasing Gold
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Chordia Therapeutics Inc. Chordia Therapeutics Inc.

Chordia Therapeutics Inc.

190A
Rang in Aktien #26476
Chordia Therapeutics Inc., a biotech company, engages in research and... Chordia Therapeutics Inc., a biotech company, engages in research and development of anti-cancer drugs that targets RNA deregulation stress in Japan. It develops CLK CTX-712, a CLK inhibitor, which is Phase 1 clinical trial for the treatment of relapsed or refractory malignant cancers.; CTX-177, a small-molecule inhibitor of MALT1; CDK12 inhibitor CTX-439; and GCN2 inhibitor CRD-1968099. Chordia Therapeutics Inc. was incorporated in 2017 and is based in Fujisawa, Japan.
Aktienkurs
$0.53499835
Marktkapitalisierung
$40.24M
Veränderung (1 Tag)
2.50%
Veränderung (1 Jahr)
-58.07%
Land
JP
Handel Chordia Therapeutics Inc. (190A)

Kategorie

Healthcare
Kursverlauf für Chordia Therapeutics Inc. (190A)
Höchster Schlusskurs: $0.53 am 2026-08-01

Niedrigster Schlusskurs: $1.06 am 2024-06-01
Kursverlauf der Aktie von Chordia Therapeutics Inc. von 2024 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2026 (TTM) 10.93%
2025 -61.05%
2024 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $539.14 36.71%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.04K 56.86%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $120.74 -14.98%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $761.87 7.04%
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $130.43 385.07%
US